Show simple item record

dc.contributor.authorWhiley, Luke
dc.contributor.authorChappell, Katie E.
dc.contributor.authorD'Hondt, Ellie
dc.contributor.authorLewis, Matthew R.
dc.contributor.authorJimenez, Beatriz
dc.contributor.authorSnowden, Stuart G.
dc.contributor.authorSoininen, Hilkka
dc.contributor.authorKloszewska, Iwona
dc.contributor.authorMecocci, Patrizia
dc.contributor.authorTsolaki, Magda
dc.contributor.authorVellas, Bruno
dc.contributor.authorSwann, Jonathan R.
dc.contributor.authorHye, Abdul
dc.contributor.authorLovestone, Simon
dc.contributor.authorLegido-Quigley, Cristina
dc.contributor.authorHolmes, Elaine
dc.date.accessioned2022-02-23T15:33:33Z
dc.date.available2022-02-23T15:33:33Z
dc.date.issued2021
dc.identifier.issn1758-9193
dc.identifier.otherWOS:000606419700001
dc.identifier.urihttps://imec-publications.be/handle/20.500.12860/39062
dc.sourceWOS
dc.titleMetabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer's disease
dc.typeJournal article
dc.contributor.imecauthorD'Hondt, Ellie
dc.contributor.orcidextWhiley, Luke::0000-0002-9088-4799
dc.contributor.orcidextLewis, Matthew R.::0000-0001-5760-5359
dc.contributor.orcidextSwann, Jonathan R.::0000-0002-6485-4529
dc.contributor.orcidextHye, Abdul::0000-0003-2237-4823
dc.contributor.orcidextLegido-Quigley, Cristina::0000-0002-4018-214X
dc.contributor.orcidimecD'Hondt, Ellie::0000-0002-1451-4569
dc.identifier.doi10.1186/s13195-020-00741-z
dc.source.numberofpages18
dc.source.peerreviewyes
dc.source.journalALZHEIMERS RESEARCH & THERAPY
dc.identifier.pmidMEDLINE:33422142
dc.source.issue1
dc.source.volume13
imec.availabilityPublished - open access


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record